T
he College of American Pathologists offers these templates to assist pathologists in providing clinically useful and relevant information when reporting results of biomarker testing. The College regards the reporting elements in the templates as important elements of the biomarker test report, but the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.
The College developed these templates as educational tools to assist pathologists in the useful reporting of relevant information. It did not issue them for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the templates might be used by hospitals, attorneys, payers, and others. The College cautions that use of the templates other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.
Also see p. 157.
TEMPLATE FOR REPORTING RESULTS OF BIOMARKER TESTING OF SPECIMENS FROM PATIENTS WITH NON-SMALL CELL CARCINOMA OF THE LUNG
Completion of the template is the responsibility of the laboratory performing the biomarker testing and/or providing the interpretation. When both testing and interpretation are performed elsewhere (eg, a reference laboratory), synoptic reporting of the results by the laboratory submitting the tissue for testing is also encouraged to ensure that all information is included in the patient's medical record and thus readily available to the treating clinical team.
BIOMARKER REPORTING TEMPLATE Lung
Select a single response unless otherwise indicated. ** This form of EGFR-activating mutation is generally associated with resistance to EGFR tyrosine kinase inhibitors although insertions at or before position 768 can be associated with sensitivity. *** This mutation is typically secondary to other EGFRactivating mutations and is associated with acquired resistance to tyrosine kinase inhibitor therapy. If seen in untreated/ pretreated patients, it may be present in the germline and indicate a hereditary cancer syndrome, in which case, genetic counseling is suggested. **** There are limited data on response to EGFR tyrosine kinase inhibitors for many of the uncommon EGFR-activating mutations.
Cannot be determined (explain): + Polysomy + Present*** * Absence of ALK rearrangement in cancer cells suggests that this tumor is unlikely to respond to treatment with a targeted inhibitor, such as crizotinib. ** ALK rearrangement predicts response to therapy with a targeted inhibitor, such as crizotinib. *** Polysomy involving the ALK locus confirms that fluorescence in situ hybridization (FISH) scoring was carried out in tumor cells but has no significance regarding response to therapy with crizotinib.
Specific codon 12 mutation not stated + Other codon 12 mutation (specify): , and time of fixation should be reported, if applicable, in this template or in the original pathology report (note F).
EXPLANATORY NOTES Background
As of 2013, more than one-half of lung adenocarcinomas contain one of a number of identifiable genetic alterations; some of those can be targeted by a specific therapeutic inhibitor that is approved either by the US Food and Drug Administration or in clinical trials. The National Comprehensive Cancer Network (NCCN) recommends testing for EGFR mutations and ALK rearrangements to guide therapy for all patients with recurrent or metastatic lung adenocarcinomas. 1 The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) have prepared a joint guideline that provides a detailed description of the patient and specimen requirements and acceptable testing designs and strategies for the detection of these alterations 2 ; the reader is referred to that guideline for details that are beyond the scope of this document.
Briefly, approximately 20% to 30% of lung adenocarcinomas contain an EGFR-activating mutation that predicts response to therapy with EGFR tyrosine kinase inhibitors, such as erlotinib. [3] [4] [5] [6] [7] [8] Up to 90% of EGFR mutations occur in 2 hot spots within the kinase domain, either as small deletions in the LREA motif of exon 19 or as a leucine to arginine substitution at amino acid 858 (exon 21).
9,10 Another~5% of lung adenocarcinomas have a chromosomal rearrangement involving the ALK gene, most commonly in the form of an intrachromosomal inversion leading to the EML4-ALK fusion product associated with ALK protein overexpression. 11 Patients with this tumor type are responsive to therapy with the multitargeted tyrosine kinase inhibitor, crizotinib. 12 Fluorescence in situ hybridization (FISH) using break-apart probes is currently considered the gold standard for detection of ALK rearrangement. 1 Currently, no targeted tyrosine kinase inhibitor therapies are specifically approved for KRAS mutations. However, KRAS testing is often performed in lung adenocarcinomas because (1) KRAS mutations are typically mutually exclusive with EGFR and ALK alterations, (2) KRAS mutations are the most common oncogenic alteration in lung adenocarcinoma (~20% to 30% of tumors), and (3) KRAS mutation testing is typically quicker, easier, and less costly than testing for EGFR and ALK. 13, 14 Therefore, KRAS mutation analysis may be used in a molecular testing algorithm to eliminate the need for other more costly and time-intensive testing.
Lung adenocarcinomas contain a number of other lesscommon alterations that may lead to treatment with targeted inhibitors but have not yet been studied in large controlled trials or emerged as the standard of care. These include chromosomal rearrangements involving ROS1 (~2% of lung adenocarcinomas, may respond to treatment with crizotinib) and RET (~2% of lung adenocarcinomas), 11 increased copies of MET, 15 and sequence altering mutations in ERBB2, BRAF, and PIK3CA. C: Polysomy.-Polysomy (multiple copies) at the ALK locus is common in lung adenocarcinoma and when present confirms that FISH has been performed in a tumor cell population. Current evidence suggests that it does not, however, predict response/resistance to targeted therapies.
D: Other Markers Tested.-''Other Markers Tested'' should be used to report results from molecular assays not included here that may be relevant to lung cancer therapy. These assays may include, but are not limited to, detection of mutations in genes, such as BRAF, ERBB2, and PIK3CA; rearrangements involving ROS1 and RET genes; and MET copy number changes (see ''Background'' section above). Procedures or fixation involving acid (eg, decalcification, Bouin) may degrade DNA. Fixation with heavy metals (eg, Zenker, B5, B+, zinc formalin) inhibits the enzymes used in PCR. Underfixation or overfixation. Fixation for at least 8 hours and less than 72 hours in buffered formalin is recommended; prolonged fixation, particularly in unbuffered formalin, degrades DNA.
